logo
Bone discovered in ancient layer of Cuban cave belonged to a new extinct species

Bone discovered in ancient layer of Cuban cave belonged to a new extinct species

Miami Herald12-05-2025

During a joint expedition to the mountains of western Cuba, researchers uncovered a rare complete bone from a bird that lived between 18,000 and 11,000 years ago.
The humerus, pulled from a well-preserved ancient layer of sediment, belonged to a new extinct species of duck named Amazonetta cubensis, or the Cuban teal, according to a May 9 study published in the peer-reviewed journal Zootaxa.
The Cuban teal is described as 'a relatively small duck' with many physical similarities to its closest living relative, the Brazilian teal, according to researcher Nikita Zelenkov.
Zelenkov said the discovery is significant because it 'for the first time indicates a wider distribution of Amazonetta ducks' during the later Quaternary period, which spanned from the later or upper Pleistocene and Holocene epochs.
According to the study, many insular or island duck species had reduced flying abilities. Experts point to a lack of island predators as the reason for this change.
The Cuban teal, however, likely never lost its ability to fly. If it did, it would 'almost certainly have been one of the main prey items of raptors and as a result would have been relatively common in the fossil record,' according to Zelenkov.
Zelenkov said duck fossils are 'extremely rare' in the West Indies, with only two other fossil ducks ever reported in Cuba.
The fossil was discovered in El Abrón Cave in Western Cuba's Pinar-del-Río province, the study said.
The extinct species was discovered in a geological layer of the cave dating back to the Late Pleistocene epoch, Zelenkov said. This particular layer is 'rich' with vertebrate remains left behind by ancient avian predators, specifically barn owls, according to the study.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

‘Long'-tailed creature gets caught in trap in India forest. It's a new species
‘Long'-tailed creature gets caught in trap in India forest. It's a new species

Miami Herald

time20 hours ago

  • Miami Herald

‘Long'-tailed creature gets caught in trap in India forest. It's a new species

Under a cover of darkness, an 'elusive' creature with a 'long' tail flew through a mountain forest in northern India — or tried to, at least. But something enveloped it and trapped it. Scientists checked their net trap and found the 'soft' animal. It turned out to be a new species. A team of researchers visited over a dozen sites in Uttarakhand and the Western Himalayas between 2017 and 2021 to survey wildlife. The region is 'one of the richest and most diverse ecosystems on Earth,' but sections of it remain 'insufficiently' studied, according to a study published June 5 in the peer-reviewed journal Zootaxa. During their surveys, researchers set up mist nets of various sizes and waited to see what flew into the traps, the study said. They also ventured into 'confined spaces like tunnels and caves' with butterfly nets to see what they could catch. 'Finally in 2021, a few days before the end of my last field season in Uttarakhand, Baseer Baniya returned from our nets with a Collared Scops-Owl bycatch in one cloth bag, and a bat that he couldn't identify in the other,' study co-author Rohit Chakravarty wrote in a June 5 Facebook post. 'As soon as I pulled the bat out of the bag,' Chakravarty knew it was an 'elusive' bat he'd seen twice before and had been searching for for years. Researchers took a closer look at the unfamiliar-looking bat, analyzed its DNA and realized they'd discovered a new species of mouse-eared bat: Myotis himalaicus, or the Himalayan long-tailed Myotis. Himalayan long–tailed Myotis bats are considered 'medium-sized,' reaching about 3.5 inches in length and weighing less than an ounce, the study said. They have 'delicate' feet and 'relatively long' thumbs ending in 'a strong but short claw.' Their heads have 'short' ears and 'rather delicate' teeth. A photo shows the new species' 'dense, soft and relatively long' hair. Overall, the mouse-eared bat's fur is 'dark brown' with some lighter hues mixed in and a paler golden-brown belly. Himalayan long–tailed Myotis bats were caught in net traps in 'a variety of forested habitats at elevations between' 4,900 to 7,500 feet and 'appears (to be) uncommon,' the study said. Much about the new species' lifestyle remains unknown. Researchers said they named the new species after the Himalayan mountains where it was first discovered. So far, Himalayan long–tailed Myotis bats have been found in Uttarakhand, India, and Khyber Pakhtunkhwa, Pakistan, locations nearly 500 miles apart. Uttarakhand is a province of northern India bordering Nepal and Tibet. The new species was identified by its DNA, tail length, body proportions, ears, skull shape, coloring and other subtle physical features, the study said. The research team included Uttam Saikia, Rohit Chakravarty, Gabor Csorba, Mostaque Ahmed Laskar and Manuel Ruedi. The team also surveyed about two dozen other bat species.

MGI Tech Expands Partnership with Fiocruz to Accelerate Advances in Epidemiological Surveillance and Personalized Medicine in Brazil
MGI Tech Expands Partnership with Fiocruz to Accelerate Advances in Epidemiological Surveillance and Personalized Medicine in Brazil

Yahoo

time2 days ago

  • Yahoo

MGI Tech Expands Partnership with Fiocruz to Accelerate Advances in Epidemiological Surveillance and Personalized Medicine in Brazil

Next-generation technologies will help increase the agility and efficiency of genetic sequencing to tackle several diseases SAO PAULO, June 5, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, has just expanded its partnership with the Diagnostic Support Unit (UNADIG), a non-profit laboratory of the Oswaldo Cruz Foundation (FIOCRUZ), one of Brazil's leading scientific institutions, to support public health in the country. MGI's first scientific collaboration with UNADIG was established during the COVID-19 pandemic. With the MGISP-960 extractor equipment from MGI, UNADIG was able to process more than 3 million samples from across the country during this period. With the end of the pandemic, UNADIG expanded its portfolio and included different methodological platforms in its laboratory facilities (chemiluminescence, Elisa, photometry, immunoturbidimetry, and indirect potentiometry), as well as genetic sequencing. The new agreement between UNADIG and MGI will enable maintain the molecular tests (RT-PCR) but advances in DNA-based testing. UNADIG has two large high-processing laboratories. The the Clinical Diagnostic Laboratory (DCLIN) has a daily processing capacity of around 29,000 samples, and the Molecular Diagnostic Laboratory (DIMOL) can process between 9,000 and 15,000 RT-PCR samples. In 2025, with the sequencing support of MGI, a process in molecular genetics will begin with the capacity to process over 2,000 samples weekly for the diagnosis of infectious, genetic, and main types of cancer (breast, ovarian, colorectal and prostate), in addition of individual gene sequencing for sporadic or hereditary cancers. "The goal of this collaboration is to help transform healthcare delivery, with a focus on efficiency and accessibility, as it will contribute to expanding access for the Brazilian population to high-complexity laboratory tests with greater speed and reduced costs. This will accelerate the diagnosis and treatment of oncological and epidemiological diseases, strengthening the country's response to outbreaks and epidemics", Carlos Carpio, Senior Commercial Director of MGI Latin America and General Manager for Brazil, explains. To expand its operational and analytical capacity for sample and test processing, UNADIG has acquired state-of-the-art equipment from MGI, including 14 units MGISP-960 nucleic acid extractor; 1 unit MGISP-100 automated genomic library preparation system; 2 units DNBSEQ-G400 and 1 unit DNBSEQ-T7 sequencers; and 1 unit ZTRON platform for genomic data storage and analysis. These technologies also ensure greater speed and accuracy in processing, while enhancing sample handling safety and reducing the risk of contamination. "Precision medicine brings significant benefits to patients and to the public health system, enabling early diagnoses, more effective treatments and the optimization of clinical protocols. This results in cost savings, waste reduction and greater effectiveness of tests and therapies. MGI's equipment, which allows automated processes, helps us achieve these goals", Erika Martins de Carvalho, General Coordinator of UNADIG-RJ of the Vice Presidency of Health Production and Innovation at Fiocruz, says. Increasing the presence in Brazil With the goal of making genetic sequencing more accessible, efficient and scalable through comprehensive solutions, MGI has been expanding its operations in Brazil. In 2024, the company inaugurated a Customer Experience Center in São Paulo, created to offer clinical laboratories and healthcare institutions a dedicated space for hands-on demonstrations. The center aims to enhance technical training and familiarity with MGI's technologies. Highly qualified professionals lead certified training sessions, presentations, evaluations and provide local support for new applications. Also in 2024, MGI established partnerships with Dasa, Grupo Sabin and Oncoclínicas&Co to expand the use of genetic sequencing in Brazil through the adoption of advanced technologies for genetic testing aimed at diagnosing cancers, rare diseases and other conditions, strengthening personalized medicine in the country. About MGI MGI Tech Co., Ltd. (or its subsidiaries, together referred to MGI), is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare and various other industries. Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and have established research, manufacturing, training, and after-sales service facilities globally. MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future. To learn more, please visit , Linkedin, X, and Youtube. View original content to download multimedia: SOURCE MGI TECH Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

MGI Tech Expands Partnership with Fiocruz to Accelerate Advances in Epidemiological Surveillance and Personalized Medicine in Brazil
MGI Tech Expands Partnership with Fiocruz to Accelerate Advances in Epidemiological Surveillance and Personalized Medicine in Brazil

Yahoo

time2 days ago

  • Yahoo

MGI Tech Expands Partnership with Fiocruz to Accelerate Advances in Epidemiological Surveillance and Personalized Medicine in Brazil

Next-generation technologies will help increase the agility and efficiency of genetic sequencing to tackle several diseases SAO PAULO, June 5, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, has just expanded its partnership with the Diagnostic Support Unit (UNADIG), a non-profit laboratory of the Oswaldo Cruz Foundation (FIOCRUZ), one of Brazil's leading scientific institutions, to support public health in the country. MGI's first scientific collaboration with UNADIG was established during the COVID-19 pandemic. With the MGISP-960 extractor equipment from MGI, UNADIG was able to process more than 3 million samples from across the country during this period. With the end of the pandemic, UNADIG expanded its portfolio and included different methodological platforms in its laboratory facilities (chemiluminescence, Elisa, photometry, immunoturbidimetry, and indirect potentiometry), as well as genetic sequencing. The new agreement between UNADIG and MGI will enable maintain the molecular tests (RT-PCR) but advances in DNA-based testing. UNADIG has two large high-processing laboratories. The the Clinical Diagnostic Laboratory (DCLIN) has a daily processing capacity of around 29,000 samples, and the Molecular Diagnostic Laboratory (DIMOL) can process between 9,000 and 15,000 RT-PCR samples. In 2025, with the sequencing support of MGI, a process in molecular genetics will begin with the capacity to process over 2,000 samples weekly for the diagnosis of infectious, genetic, and main types of cancer (breast, ovarian, colorectal and prostate), in addition of individual gene sequencing for sporadic or hereditary cancers. "The goal of this collaboration is to help transform healthcare delivery, with a focus on efficiency and accessibility, as it will contribute to expanding access for the Brazilian population to high-complexity laboratory tests with greater speed and reduced costs. This will accelerate the diagnosis and treatment of oncological and epidemiological diseases, strengthening the country's response to outbreaks and epidemics", Carlos Carpio, Senior Commercial Director of MGI Latin America and General Manager for Brazil, explains. To expand its operational and analytical capacity for sample and test processing, UNADIG has acquired state-of-the-art equipment from MGI, including 14 units MGISP-960 nucleic acid extractor; 1 unit MGISP-100 automated genomic library preparation system; 2 units DNBSEQ-G400 and 1 unit DNBSEQ-T7 sequencers; and 1 unit ZTRON platform for genomic data storage and analysis. These technologies also ensure greater speed and accuracy in processing, while enhancing sample handling safety and reducing the risk of contamination. "Precision medicine brings significant benefits to patients and to the public health system, enabling early diagnoses, more effective treatments and the optimization of clinical protocols. This results in cost savings, waste reduction and greater effectiveness of tests and therapies. MGI's equipment, which allows automated processes, helps us achieve these goals", Erika Martins de Carvalho, General Coordinator of UNADIG-RJ of the Vice Presidency of Health Production and Innovation at Fiocruz, says. Increasing the presence in Brazil With the goal of making genetic sequencing more accessible, efficient and scalable through comprehensive solutions, MGI has been expanding its operations in Brazil. In 2024, the company inaugurated a Customer Experience Center in São Paulo, created to offer clinical laboratories and healthcare institutions a dedicated space for hands-on demonstrations. The center aims to enhance technical training and familiarity with MGI's technologies. Highly qualified professionals lead certified training sessions, presentations, evaluations and provide local support for new applications. Also in 2024, MGI established partnerships with Dasa, Grupo Sabin and Oncoclínicas&Co to expand the use of genetic sequencing in Brazil through the adoption of advanced technologies for genetic testing aimed at diagnosing cancers, rare diseases and other conditions, strengthening personalized medicine in the country. About MGI MGI Tech Co., Ltd. (or its subsidiaries, together referred to MGI), is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare and various other industries. Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and have established research, manufacturing, training, and after-sales service facilities globally. MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future. To learn more, please visit , Linkedin, X, and Youtube. View original content to download multimedia: SOURCE MGI TECH Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store